CT-Guided Interstitial HDR Brachytherapy for Malignant Lung Lesions: Experience from University of California Los Angeles

Yoon, Sangpil; Deng, Jie; Wong, Kirsten; Lee, Alan; Venkat, Puja; Chang, Albert

doi:10.1007/978-3-030-78079-1_13

Cited by 1 publication

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 2005, a limited number of case series have been reported in the literature demonstrating the safety and efficacy of percutaneous HDR brachyablation for lung tumors [8,[10][11][12][13]. Our institution has been delivering this treatment since 2015, and published our initial outcomes in 2021 for 25 patients with 37 pulmonary tumors treated [9]. In that report, the 2-year local control rate with upfront HDR brachyablation of lung tumors was 96%, with no patients developing a major complication.…”

Section: Purposementioning

confidence: 99%

“…Secondary treatment options for isolated primary tumor site progression after SBRT include salvage lung resection, re-irradiation with external beam radiation therapy (EBRT), or percutaneous ablative procedures (cryotherapy, microwave ablation, radio-frequency ablation) [6,7]. A more novel approach is percutaneous high-dose-rate (HDR) brachyablation that is a minimally invasive treatment involving implantation of temporary catheters into lung tumors to deliver high doses of radio-therapy in a single fraction with minimal exposure of previously irradiated tissues [8,9].…”

Section: Purposementioning

confidence: 99%

See 1 more Smart Citation

Salvage percutaneous high-dose-rate brachyablation after stereotactic body radiation therapy for early-stage non-small cell lung cancer

Wu,

Lee,

Suh

et al. 2024

jcb

View full text Add to dashboard Cite

Patients with primary tumor progression after stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC) have a second chance at complete tumor eradication with salvage local therapies, including lung resection, repeat course of SBRT, and percutaneous ablative therapies. In this paper, we presented our institution’s initial experience with percutaneous high-dose-rate (HDR) brachyablation for a relapsed stage I NSCLC that had been treated with SBRT 4.3 years earlier. Lung tumor measuring approximately 5 cm in maximum tumor dimension at the time of relapse was histopathologically confirmed to be persistent squamous cell carcinoma, and successfully treated with a single fraction of 24 Gy with HDR brachyablation. Treatment was delivered via two percutaneous catheters inserted under CT-guidance, and treated in less than 20 minutes. The patient was discharged home later the same day without the need for a chest tube, and has been monitored with serial surveillance scans every 3 to 6 months without evidence of further lung cancer progression or complications at 2.8 years post-HDR brachyablation procedure and 7.8 years after initial SBRT.

show abstract